5Kinlay S,Selwyn AP,Delagrange D,et al.Biological mechanisms for the clinical success of lipid lowering in coronary artery disease and the use of surrogate and points[J].Cur Opin Lipidol,1996,7:389-397.
6Hackman A,Abe Y,Insullw JR,et al.Levels of soluble cell adnesion molecules in Patients with dyslipidemi[J].Circulation,1996,83:1334-1338.
7Lea AP,Mc tacish D.Atorvastatin a review of its pharmacology and therapeutic potential in the management of hyperlipidemias[J].Drugs,1997,53:828-847.
8LizzoI G,Biasuccil L M,Gallimore J R,et al.The prognostic value of C-reative protein and serum amyloid-A ptrotein in severe unstable angina[J].N Engl J Med,1994,331:417-424.
9Haverkate F,Thompson SG,Pyke SD.et al.Production of C-reactive protein and risk of corenary events in stable and unstable angina:European concented action on thrombosis and disabilities angina pectoris study group[J].Lancet,1997,349:462-466.
10Hoffmelster H M,Ehlers R,Butjttcher E,et al.Comparison of Creactive Protein and terminal complement complex in Patients with unstable angina Pectoris versus stable angina pectoris[J].Am J Cardiol,2002,89:909-912.
